Pfizer Inc. (PFE)
Pfizer: The Great Healthcare Plan Does Not Change My Bullish Stance
The Great Healthcare Plan has threatened the biopharma sector with mandatory global price parity, but the market is overlooking a critical carve-out specific to Pfizer. While competitors face immediate tariff risks, Pfizer's negotiated 3-year exemption from Section 232 and the potential dismantling of the PBM rebate model create an underappreciated margin defense. I explain why the launch of TrumpRx.gov is a volume opportunity rather than a revenue threat, reinforcing my bullish thesis despite the headline regulatory noise.
Pfizer: Expect Another Double Beating For Q1 (Earnings Preview)
Pfizer (PFE) remains a 'Buy' ahead of its fiscal Q1 2027 earnings, with the stock deeply discounted and consensus estimates overly pessimistic. LOE headwinds are significant but phased, while cost savings ($7.7B by 2027) and pipeline catalysts offer margin and revenue offsets. Pipeline momentum—especially in obesity, oncology, and vaccines—could drive narrative shifts and repricing if key 2026 readouts succeed.
Pfizer (PFE) Outperforms Broader Market: What You Need to Know
Pfizer (PFE) closed the most recent trading day at $25.9, moving +1.49% from the previous trading session.
MoneyShow's Best Investment Ideas For 2026: Part 7
MoneyShow presents top investment ideas for 2026 from their contributors. This year's edition presents a mix of metals plays, financial stocks, deep value names, high-octane growth and tech stocks, and beaten-down REITs that offer solid income and turnaround potential. Part 7 of this series includes Pfizer, Philip Morris International, Platinum Group Metals, Prologis and QuickLogic Corp.
What to Expect From Pfizer's Non-Oncology Business in Q4?
PFE's Q4 outlook centers on Eliquis growth, softer COVID-19 sales and steady demand for key non-oncology drugs ahead of earnings.
Pfizer: Rebound Has Just Started
Pfizer has outperformed the S&P 500 since my previous call, driven by improving fundamentals and renewed share price momentum. Positive developments around the pipeline support long-term financial stability, reinforcing confidence in PFE's outlook. PFE's substantial 6.7% forward dividend yield appears secure, offering attractive income in a volatile market.
Pfizer: The Most Intriguing Value Play Of 2026
Pfizer remains a Strong Buy, with oncology breakthroughs, a revitalized obesity pipeline, and aggressive cost savings supporting a compelling value thesis. BRAFTOVI's Phase 3 success and PADCEV + Keytruda's expanded indications position PFE for blockbuster growth in precision oncology. The obesity pipeline, including MET-097i and a new oral candidate, could catalyze a major re-rating if Phase 3 data are positive.
Pfizer (PFE) Ascends While Market Falls: Some Facts to Note
In the latest trading session, Pfizer (PFE) closed at $25.56, marking a +1.63% move from the previous day.
PFE Market Cap Falls More Than $7B in a Month: How to Play the Stock
Pfizer shares fall nearly 5% in a month after weak 2026 guidance, sparking debate over buying the dip or staying cautious.
Pfizer's Patent Cliff, Rising Debt, And The Fight To Stay A Buy
Pfizer remains a 'Buy' at current low valuation multiples, but faces significant headwinds from an impending patent cliff through 2030. Pfizer's top-line growth is challenged by steep declines in COVID product sales and upcoming loss of exclusivity for key drugs like Eliquis and Ibrance. The $7B Metsera acquisition stretches Pfizer's balance sheet, limiting future buybacks and major acquisitions while aiming to offset revenue declines.
Pfizer CEO plans for soaring consumer market for obesity drugs akin to Viagra
Pfizer is preparing for a consumer market for obesity drugs on par with the booming business it saw after it launched erectile dysfunction drug Viagra in 1998, CEO Albert Bourla said on Monday.
Pfizer Inc. (PFE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Pfizer Inc. (PFE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
